The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Localized Prostate Cancer
Advertisement
Latest News
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options.
Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance.
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Advertisement
Advertisement
Trending
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.